Nutrition Research and Practice

The Korean Nutrition Society (한국영양학회)
권호 표지
DOI QR코드

DOI QR Code

Mixture of Corni Fructus and Schisandrae Fructus improves testosterone-induced benign prostatic hyperplasia through regulating 5α-reductase 2 and androgen receptor

  • Hyun Hwangbo (Korea Nanobiotechnology Center, Pusan National University) ;
  • Min Yeong Kim (Department of Biochemistry, Dong-eui University College of Korean Medicine) ;
  • Seon Yeong Ji (Department of Biochemistry, Dong-eui University College of Korean Medicine) ;
  • Beom Su Park (Department of Biochemistry, Dong-eui University College of Korean Medicine) ;
  • TaeHee Kim (Hamsoapharm Central Research) ;
  • Seonhye Yoon (R&D Center, Naturetech Co. Ltd.) ;
  • Hyunjin Kim (R&D Center, Naturetech Co. Ltd.) ;
  • Sung Yeon Kim (BIO Center, Chungbuk Technopark) ;
  • Haeun Jung (BIO Center, Chungbuk Technopark) ;
  • Taeiung Kim (BIO Center, Chungbuk Technopark) ;
  • Hyesook Lee (Department of Biochemistry, Dong-eui University College of Korean Medicine) ;
  • Gi-Young Kim (Department of Marine Life Science, Jeju National University) ;
  • Yung Hyun Choi (Department of Biochemistry, Dong-eui University College of Korean Medicine)
  • Received : 2022.01.05
  • Accepted : 2022.06.15
  • Published : 2023.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

BACKGROUND/OBJECTIVES: Benign prostatic hyperplasia (BPH) characterized by an enlarged prostate gland is common in elderly men. Corni Fructus (CF) and Schisandrae Fructus (SF) are known to have various pharmacological effects, including antioxidant and anti-inflammatory activities. In this study, we evaluated the inhibitory efficacy of CF, SF, and their mixture (MIX) on the development of BPH using an in vivo model of testosterone-induced BPH. MATERIALS/METHODS: Six-week-old male Sprague-Dawley rats were randomly divided into seven groups. To induce BPH, testosterone propionate (TP) was injected to rats except for those in the control group. Finasteride, saw palmetto (SP), CF, SF, and MIX were orally administered along with TP injection. At the end of treatment, histological changes in the prostate and the level of various biomarkers related to BPH were evaluated. RESULTS: Our results showed that BPH induced by TP led to prostate weight and histological changes. Treatment with MIX effectively improved TP-induced BPH by reducing prostate index, lumen area, epithelial thickness, and expression of BPH biomarkers such as 5α-reductase type 2, prostate-specific antigen, androgen receptor, and proliferating cell nuclear antigen compared to treatment with CF or SF alone. Moreover, MIX further reduced levels of elevated serum testosterone, dihydrotestosterone, and prostate-specific antigen in BPH compared to the SP, a positive control. BPH was also improved more by MIX than by CF or SF alone. CONCLUSIONS: Based on the results, MIX is a potential natural therapeutic candidate for BPH by regulating 5α-reductase and AR signaling pathway.

Keywords

Acknowledgement

This research was financially supported by the Ministry of Small and Medium-sized Enterprises (SMEs) and Startups (MSS), Korea, under the "Regional Specialized Industry Development Plus Program (R&D, S2874684) supervised by the Korea Institute for Advancement of Technology (KIAT).

References

  1. Sharma M, Chadha R, Dhingra N. Phytotherapeutic agents for benign prostatic hyperplasia: an overview. Mini Rev Med Chem 2017;17:1346-63. https://doi.org/10.2174/1389557516666160621103817
  2. Vickman RE, Franco OE, Moline DC, Vander Griend DJ, Thumbikat P, Hayward SW. The role of the androgen receptor in prostate development and benign prostatic hyperplasia: a review. Asian J Urol 2020;7:191-202. https://doi.org/10.1016/j.ajur.2019.10.003
  3. Vasanwala FF, Wong MY, Ho HS, Foo KT. Benign prostatic hyperplasia and male lower urinary symptoms: a guide for family physicians. Asian J Urol 2017;4:181-4. https://doi.org/10.1016/j.ajur.2017.05.003
  4. Mobley D, Feibus A, Baum N. Benign prostatic hyperplasia and urinary symptoms: evaluation and treatment. Postgrad Med 2015;127:301-7. https://doi.org/10.1080/00325481.2015.1018799
  5. Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology 2019;65:458-64. https://doi.org/10.1159/000496289
  6. Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci 2009;1155:43-56.  https://doi.org/10.1111/j.1749-6632.2009.04115.x
  7. Cozar JM, Hernandez C, Minana B, Morote J, Alvarez-Cubero MJ. The role of prostate-specific antigen in light of new scientific evidence: an update in 2020. Actas Urol Esp (Engl Ed) 2021;45:21-9. https://doi.org/10.1016/j.acuro.2020.09.005
  8. Kizilay F, Kalemci MS, Simsir A, Turna B, Nazli O, Berdeli A. The place of androgen receptor gene mutation analysis in the molecular diagnosis of prostate cancer and genotype-phenotype relationship. Turk J Med Sci 2014;44:261-6. https://doi.org/10.3906/sag-1210-97
  9. La Vignera S, Aversa A, Cannarella R, Condorelli RA, Duca Y, Russo GI, Calogero AE. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother 2021;22:179-89. https://doi.org/10.1080/14656566.2020.1817382
  10. De Nunzio C, Presicce F, Tubaro A. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia. Drugs Today (Barc) 2016;52:501-17. https://doi.org/10.1358/dot.2016.52.9.2525739
  11. Gupta S, Gupta G, Sharma VL. Evolving novel chemical entities for management of benign prostatic hyperplasia. Mini Rev Med Chem 2017;17:593-602. https://doi.org/10.2174/1389557516666160630115819
  12. Garg G, Singh D, Saraf S, Saraf S. Management of benign prostate hyperplasia: an overview of alphaadrenergic antagonist. Biol Pharm Bull 2006;29:1554-8. https://doi.org/10.1248/bpb.29.1554
  13. Azzouni F, Mohler J. Role of 5α-reductase inhibitors in benign prostatic diseases. Prostate Cancer Prostatic Dis 2012;15:222-30. https://doi.org/10.1038/pcan.2012.1
  14. Traish AM, Mulgaonkar A, Giordano N. The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol 2014;55:367-79. https://doi.org/10.4111/kju.2014.55.6.367
  15. Gao X, Liu Y, An Z, Ni J. Active components and pharmacological effects of Cornus officinalis: literature review. Front Pharmacol 2021;12:633447.
  16. Dong Y, Feng ZL, Chen HB, Wang FS, Lu JH. Corni Fructus: a review of chemical constituents and pharmacological activities. Chin Med 2018;13:34.
  17. Kopustinskiene DM, Bernatoniene J. Antioxidant effects of Schisandra chinensis fruits and their active constituents. Antioxidants 2021;10:620.
  18. Rybnika? M, Smejkal K, Zemlicka M. Schisandra chinensis and its phytotherapeutical applications. Ceska Slov Farm 2019;68:95-118.
  19. Huang J, Zhang Y, Dong L, Gao Q, Yin L, Quan H, Chen R, Fu X, Lin D. Ethnopharmacology, phytochemistry, and pharmacology of Cornus officinalis Sieb. et Zucc. J Ethnopharmacol 2018;213:280-301. https://doi.org/10.1016/j.jep.2017.11.010
  20. Zhou Y, Men L, Sun Y, Wei M, Fan X. Pharmacodynamic effects and molecular mechanisms of lignans from Schisandra chinensis Turcz. (Baill.), a current review. Eur J Pharmacol 2021;892:173796.
  21. Mitsunari K, Miyata Y, Matsuo T, Mukae Y, Otsubo A, Harada J, Kondo T, Matsuda T, Ohba K, Sakai H. Pharmacological effects and potential clinical usefulness of polyphenols in benign prostatic hyperplasia. Molecules 2021;26:450.
  22. Castelli T, Russo GI, Reale G, Privitera S, Chisari M, Fragala E, Favilla V, Cimino S, Morgia G. Metabolic syndrome and prostatic disease: potentially role of polyphenols in preventive strategies. A review. Int Braz J Urol 2016;42:422-30. https://doi.org/10.1590/S1677-5538.IBJU.2015.0095
  23. Minciullo PL, Inferrera A, Navarra M, Calapai G, Magno C, Gangemi S. Oxidative stress in benign prostatic hyperplasia: a systematic review. Urol Int 2015;94:249-54. https://doi.org/10.1159/000366210
  24. Bostanci Y, Kazzazi A, Momtahen S, Laze J, Djavan B. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 2013;23:5-10.   https://doi.org/10.1097/MOU.0b013e32835abd4a
  25. Hwangbo H, Kwon DH, Choi EO, Kim MY, Ahn KI, Ji SY, Kim JS, Kim KI, Park NJ, Kim BH, et al. Corni Fructus attenuates testosterone-induced benign prostatic hyperplasia by suppressing 5α-reductase and androgen receptor expression in rats. Nutr Res Pract 2018;12:378-86. https://doi.org/10.4162/nrp.2018.12.5.378
  26. Wei F, He X, Xu K, Wang S. Stepwise frontal analysis coupled with cell membrane chromatography for affinity screening and characterization analysis of bioactive constituent from the mature fruits of schisandra chinensis. J Chromatogr B Analyt Technol Biomed Life Sci 2020;1161:122443.
  27. Bandiera S, Pulcinelli RR, Huf F, Almeida FB, Halmenschlager G, Bitencourt PE, Dallegrave E, C Fernandes M, Gomez R, Nin MS. Hepatic and renal damage by alcohol and cigarette smoking in rats. Toxicol Res 2020;37:209-19. https://doi.org/10.1007/s43188-020-00057-y
  28. Bhat A, Blachman-Braun R, Herrmann TR, Shah HN. Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction. World J Urol 2022;40:889-905. https://doi.org/10.1007/s00345-021-03771-w
  29. Gravina GL, Mancini A, Ranieri G, Di Pasquale B, Marampon F, Di Clemente L, Ricevuto E, Festuccia C. Phenotypic characterization of human prostatic stromal cells in primary cultures derived from human tissue samples. Int J Oncol 2013;42:2116-22. https://doi.org/10.3892/ijo.2013.1892
  30. Zhou Y, Xiao XQ, Chen LF, Yang R, Shi JD, Du XL, Klocker H, Park I, Lee C, Zhang J. Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats. Asian J Androl 2009;11:451-9. https://doi.org/10.1038/aja.2009.28
  31. Rodriguez-Nieves JA, Macoska JA. Prostatic fibrosis, lower urinary tract symptoms, and BPH. Nat Rev Urol 2013;10:546-50. https://doi.org/10.1038/nrurol.2013.149
  32. Song KH, Seo CS, Yang WK, Gu HO, Kim KJ, Kim SH. Extracts of Phyllostachys pubescens leaves represses human steroid 5-α reductase type 2 promoter activity in BHP-1 cells and ameliorates testosterone-induced benign prostatic hyperplasia in rat model. Nutrients 2021;13:884.
  33. Kim DG, Kwon HJ, Lim JH, Kim JH, Lee KP. Quisqualis indica extract ameliorates low urinary tract symptoms in testosterone propionate-induced benign prostatic hyperplasia rats. Lab Anim Res 2020;36:26.
  34. Kim HJ, Jin BR, An HJ. Psoralea corylifolia L. extract ameliorates benign prostatic hyperplasia by regulating prostate cell proliferation and apoptosis. J Ethnopharmacol 2021;273:113844.
  35. Hong GL, Park SR, Jung DY, Karunasagara S, Lee KP, Koh EJ, Cho K, Park SS, Jung JY. The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5α-reductase type 2. J Ethnopharmacol 2020;250:112446.
  36. Choi YJ, Kim EK, Fan M, Tang Y, Hwang YJ, Sung SH. Effect of Paecilomyces tenuipes extract on testosteroneinduced benign prostatic hyperplasia in Sprague-Dawley rats. Int J Environ Res Public Health 2019;16:3764.
  37. Lee G, Shin J, Choi H, Jo A, Pan S, Bae D, Lee Y, Choi C. Cynanchum wilfordii ameliorates testosteroneinduced benign prostatic hyperplasia by regulating 5α-reductase and androgen receptor activities in a rat model. Nutrients 2017;9:1070.
  38. Karunasagara S, Hong GL, Jung DY, Kim KH, Cho K, Jung JY. Protective effects of combination of Stauntonia hexaphylla and Cornus officinalis on testosterone-induced benign prostatic hyperplasia through inhibition of 5α- reductase type 2 and induced cell apoptosis. PLoS One 2020;15:e0236879.
  39. Uroko RI, Chukwu CN, Egba SI, Adamude FA, Ajuzie JC. Combined ethanol extract of Funtumia africana and Abutilon mauritianium leaves improves the lipid profile and kidney function indices of benign prostatic hyperplasia in rats. Acta Sci Pol Technol Aliment 2020;19:395-404.   https://doi.org/10.17306/J.AFS.2020.0819
  40. Cai H, Cao G, Cai B. Rapid simultaneous identification and determination of the multiple compounds in crude Fructus Corni and its processed products by HPLC-MS/MS with multiple reaction monitoring mode. Pharm Biol 2013;51:273-8. https://doi.org/10.3109/13880209.2012.720689
  41. Liu H, Lai H, Jia X, Liu J, Zhang Z, Qi Y, Zhang J, Song J, Wu C, Zhang B, et al. Comprehensive chemical analysis of Schisandra chinensis by HPLC-DAD-MS combined with chemometrics. Phytomedicine 2013;20:1135-43. https://doi.org/10.1016/j.phymed.2013.05.001
  42. Kim DU, Kim DG, Choi JW, Shin JY, Kweon B, Zhou Z, Lee HS, Song HJ, Bae GS, Park SJ. Loganin attenuates the severity of acute kidney injury induced by cisplatin through the inhibition of ERK activation in mice. Int J Mol Sci 2021;22:1421.
  43. Cheng YC, Chiu YM, Dai ZK, Wu BN. Loganin ameliorates painful diabetic neuropathy by modulating oxidative stress, inflammation and insulin sensitivity in streptozotocin-nicotinamide-induced diabetic rats. Cells 2021;10:2688.
  44. Nasser MI, Han T, Adlat S, Tian Y, Jiang N. Inhibitory effects of Schisandrin B on human prostate cancer cells. Oncol Rep 2019;41:677-85.
  45. Mahapokai W, Van Sluijs FJ, Schalken JA. Models for studying benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2000;3:28-33. https://doi.org/10.1038/sj.pcan.4500391
  46. Zhang J, Zhang M, Tang J, Yin G, Long Z, He L, Zhou C, Luo L, Qi L, Wang L. Animal models of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2021;24:49-57. https://doi.org/10.1038/s41391-020-00277-1
  47. Soni KK, Shin YS, Choi BR, Karna KK, Kim HK, Lee SW, Kim CY, Park JK. Protective effect of DA-9401 in finasteride-induced apoptosis in rat testis: inositol requiring kinase 1 and c-Jun N-terminal kinase pathway. Drug Des Devel Ther 2017;11:2969-79. https://doi.org/10.2147/DDDT.S140543
  48. Messner EA, Steele TM, Tsamouri MM, Hejazi N, Gao AC, Mudryj M, Ghosh PM. The androgen receptor in prostate cancer: effect of structure, ligands and spliced variants on therapy. Biomedicines 2020;8:422.
  49. Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH, Te AE, Kaplan SA. Benign prostatic hyperplasia. Nat Rev Dis Primers 2016;2:16031.
  50. Soulitzis N, Karyotis I, Delakas D, Spandidos DA. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia. Int J Oncol 2006;29:305-14. https://doi.org/10.3892/ijo.29.2.305
  51. Minutoli L, Rinaldi M, Marini H, Irrera N, Crea G, Lorenzini C, Puzzolo D, Valenti A, Pisani A, Adamo EB, et al. Apoptotic pathways linked to endocrine system as potential therapeutic targets for benign prostatic hyperplasia. Int J Mol Sci 2016;17:1311.
  52. Jin BR, Cheon SY, Kim HJ, Kim MS, Lee KH, An HJ. Anti-proliferative effects of standardized Cornus officinalis on benign prostatic epithelial cells via the PCNA/E2F1-dependent cell cycle pathway. Int J Mol Sci 2020;21:9567.
  53. Choo SH, Sung HH, Chae MR, Kang SJ, Han DH, Park JK, So I, Lee SW. Effects of Schisandra chinensis extract on the relaxation of isolated human prostate tissue and smooth muscle cell. J Ethnopharmacol 2014;156:271-6.   https://doi.org/10.1016/j.jep.2014.08.025